Dr Fredrik Schjesvold speaks to ecancer about understanding the remaining unmet needs in a post ASCT NDMM setting.

Current post-transplant practices emphasize induction and consolidation treatments, with consolidation being a standard yet variably defined approach.

A study on CAR T-cell therapy for consolidation was halted due to the effectiveness of existing treatments.

Maintenance therapy now incorporates daratumumab and lenalidomide, with reimbursement discussions ongoing in Europe.

Future options may include bispecifics and newer drugs, which promise easier management and fewer side effects.